Xilio Therapeutics (XLO) Stock Forecast, Price Target & Predictions
XLO Stock Forecast
Xilio Therapeutics stock forecast is as follows: an average price target of $7.00 (represents a 643.73% upside from XLO’s last price of $0.94) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
XLO Price Target
XLO Analyst Ratings
Buy
Xilio Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 21, 2022 | - | Chardan Capital | $7.00 | $1.97 | 255.33% | 643.73% |
10
Xilio Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.94 | $0.94 | $0.94 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Dec 21, 2022 | Chardan Capital | - | Buy | Initialise |
10
Xilio Therapeutics Financial Forecast
Xilio Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - |
Avg Forecast | $40.40M | $2.90M | $2.90M | $2.90M | $3.30M | $3.30M | $30.00M | $30.00M |
High Forecast | $40.40M | $2.90M | $2.90M | $2.90M | $3.30M | $3.30M | $30.00M | $30.00M |
Low Forecast | $40.40M | $2.90M | $2.90M | $2.90M | $3.30M | $3.30M | $30.00M | $30.00M |
# Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - |
Forecast
Xilio Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - |
Forecast
Xilio Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - |
Avg Forecast | $317.32K | $-9.84M | $-8.89M | $-8.57M | $-14.17M | $-15.65M | $-14.60M | $-6.98M |
High Forecast | $317.32K | $-9.84M | $-8.89M | $-8.57M | $-10.95M | $-15.65M | $-14.60M | $-6.98M |
Low Forecast | $317.32K | $-9.84M | $-8.89M | $-8.57M | $-16.75M | $-15.65M | $-14.60M | $-6.98M |
Surprise % | - | - | - | - | - | - | - | - |
Forecast
Xilio Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - |
Forecast
Xilio Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - |
Avg Forecast | $0.01 | $-0.15 | $-0.14 | $-0.14 | $-0.22 | $-0.25 | $-0.23 | $-0.11 |
High Forecast | $0.01 | $-0.15 | $-0.14 | $-0.14 | $-0.17 | $-0.25 | $-0.23 | $-0.11 |
Low Forecast | $0.01 | $-0.15 | $-0.14 | $-0.14 | $-0.26 | $-0.25 | $-0.23 | $-0.11 |
Surprise % | - | - | - | - | - | - | - | - |
Forecast
Xilio Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
RAPT | RAPT Therapeutics | $1.07 | $30.71 | 2770.09% | Hold |
XLO | Xilio Therapeutics | $0.94 | $7.00 | 644.68% | Buy |
ANTX | AN2 Therapeutics | $1.30 | $8.75 | 573.08% | Buy |
MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
AVTE | Aerovate Therapeutics | $2.66 | $13.00 | 388.72% | Hold |
ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
ADAG | Adagene | $2.09 | $5.00 | 139.23% | Buy |
MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
TYRA | Tyra Biosciences | $15.87 | $31.75 | 100.06% | Buy |
DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
CNTB | Connect Biopharma | $1.05 | $1.50 | 42.86% | Buy |
EWTX | Edgewise Therapeutics | $31.95 | $45.00 | 40.85% | Buy |
IKNA | Ikena Oncology | $1.70 | $1.33 | -21.76% | Buy |
CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |